12:00 PM EST - Acasti Pharma : announced its financial results for the first quarter ended May 31, 2013. Revenues were $6,000, versus $14,000 for the quarter ended May 31, 2012. Sales in both years were generated from the commercialization of Onemia™, the Corporation's medical food product. Adjusted EBITDA was negative $1,260,000 for the quarter ended May 31, 2013, versus negative $916,000 in the corresponding prior-year quarter. A net loss of $1,965,000 or $0.03 per share was recorded for the current quarter, versus a net loss of $1,576,000 or $0.02 per share in the same quarter last year. Acasti Pharma
shares V.APO are trading unchanged at $3.25.
